News | July 23, 2014

Cholesterol-lowering Drugs May Reduce Cardiovascular Death in Type 2 Diabetes

statins, pharmaceuticals, cholesterol
Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. In fact, at least 65 percent of people with diabetes die from some form of heart disease or stroke, according to the American Heart Association.
 
However, a new study by researchers at Wake Forest Baptist Medical Center suggests that the use of cholesterol-lowering statins may help prolong the lives of people with diabetic cardiovascular disease. The study is published in the current online edition of Diabetes Care.
 
“Although our study was not a clinical trial, it did show that people with diabetes and heart disease can still live quite a few years by taking statins,” said Don Bowden, Ph.D., professor of biochemistry at Wake Forest Baptist and lead author of the study.
 
The research team studied data from 371 patients who had participated in the Diabetes Heart Study. At the beginning of the study, the participants received a CT scan to determine their levels of coronary artery calcium (CAC); a CAC score greater than 1,000 indicates an increased risk for cardiovascular disease (CVD). The team compared the baseline characteristics of 153 patients who died during an average 8.2 years of follow-up and 218 who survived. The researchers assumed that risk for mortality would be consistently high among the study participants. However, 60 percent were still living after more than eight years.
 
The use of cholesterol-lowering statins at the baseline exam was the only modifiable risk factor identified to be protective against mortality. The participants taking statins at the beginning of the study had a 50 percent increase of being alive as compared to those who did not.
 
Bowden said this highlights the importance of widespread prescription of cholesterol-lowering medications among individuals with Type 2 diabetes who have existing high CVD risk, but added that in previous studies the rates of statins prescribed for diabetic patients have been low.
 
“These data suggest that cholesterol-lowering medications may be used less than recommended and need to be more aggressively targeted as a critical modifiable risk factor,” he said.
 
Funding for the study was provided by National Institutes of Health grants R01-HL-67348, R01-HL-092301 and R01-N5-058700. Co-authors of the study are Amanda Cox, Ph.D., Fang-Ci Hsu, Ph.D., Barry Freedman, M.D., and David Herrington, M.D., of Wake Forest Baptist; J. Jeffrey Carr, M.D., of Vanderbilt University School of Medicine; and Michael Criqui, M.D., of the University of California, San Diego.
 
For more information: www.wakehealth.edu
 

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Overlay Init